LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study.

    Rayner, Fiona / Anderson, Amy E / Baker, Kenneth F / Buckley, Christopher D / Dyke, Bernard / Fenton, Sally / Filer, Andrew / Goodyear, Carl S / Hilkens, Catharien M U / Hiu, Shaun / Kerrigan, Sean / Kurowska-Stolarska, Mariola / Matthews, Fiona / McInnes, Iain / Ng, Wan-Fai / Pratt, Arthur G / Prichard, Jonathan / Raza, Karim / Siebert, Stefan /
    Stocken, Deborah / Teare, M Dawn / Young, Stephen / Isaacs, John D

    BMC rheumatology

    2021  Volume 5, Issue 1, Page(s) 22

    Abstract: Background: Our knowledge of immune-mediated inflammatory disease (IMID) aetiology and pathogenesis has improved greatly over recent years, however, very little is known of the factors that trigger disease relapses (flares), converting diseases from ... ...

    Abstract Background: Our knowledge of immune-mediated inflammatory disease (IMID) aetiology and pathogenesis has improved greatly over recent years, however, very little is known of the factors that trigger disease relapses (flares), converting diseases from inactive to active states. Focussing on rheumatoid arthritis (RA), the challenge that we will address is why IMIDs remit and relapse. Extrapolating from pathogenetic factors involved in disease initiation, new episodes of inflammation could be triggered by recurrent systemic immune dysregulation or locally by factors within the joint, either of which could be endorsed by overarching epigenetic factors or changes in systemic or localised metabolism.
    Methods: The BIO-FLARE study is a non-randomised longitudinal cohort study that aims to enrol 150 patients with RA in remission on a stable dose of non-biologic disease-modifying anti-rheumatic drugs (DMARDs), who consent to discontinue treatment. Participants stop their DMARDs at time 0 and are offered an optional ultrasound-guided synovial biopsy. They are studied intensively, with blood sampling and clinical evaluation at weeks 0, 2, 5, 8, 12 and 24. It is anticipated that 50% of participants will have a disease flare, whilst 50% remain in drug-free remission for the study duration (24 weeks). Flaring participants undergo an ultrasound-guided synovial biopsy before reinstatement of previous treatment. Blood samples will be used to investigate immune cell subsets, their activation status and their cytokine profile, autoantibody profiles and epigenetic profiles. Synovial biopsies will be examined to profile cell lineages and subtypes present at flare. Blood, urine and synovium will be examined to determine metabolic profiles. Taking into account all generated data, multivariate statistical techniques will be employed to develop a model to predict impending flare in RA, highlighting therapeutic pathways and informative biomarkers. Despite initial recruitment to time and target, the SARS-CoV-2 pandemic has impacted significantly, and a decision was taken to close recruitment at 118 participants with complete data.
    Discussion: This study aims to investigate the pathogenesis of flare in rheumatoid arthritis, which is a significant knowledge gap in our understanding, addressing a major unmet patient need.
    Trial registration: The study was retrospectively registered on 27/06/2019 in the ISRCTN registry 16371380 .
    Language English
    Publishing date 2021-07-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 2918121-5
    ISSN 2520-1026 ; 2520-1026
    ISSN (online) 2520-1026
    ISSN 2520-1026
    DOI 10.1186/s41927-021-00194-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis.

    Juarez, Maria / Bang, Holger / Hammar, Friederike / Reimer, Ulf / Dyke, Bernard / Sahbudin, Ilfita / Buckley, Christopher D / Fisher, Benjamin / Filer, Andrew / Raza, Karim

    Annals of the rheumatic diseases

    2015  Volume 75, Issue 6, Page(s) 1099–1107

    Abstract: Objective: To investigate serum antibody reactivity against a panel of post-translationally modified vimentin peptides (PTMPs) in patients with early inflammatory arthritis.: Methods: A panel of PTMPs was developed. Microtitre plates were coated with ...

    Abstract Objective: To investigate serum antibody reactivity against a panel of post-translationally modified vimentin peptides (PTMPs) in patients with early inflammatory arthritis.
    Methods: A panel of PTMPs was developed. Microtitre plates were coated with peptides derived from vimentin that were identical in length and composition except at one amino acid that was changed to introduce one of three post-translational modifications (PTMs)-either a citrullinated, carbamylated or acetylated residue. Sera of 268 treatment-naive patients with early inflammatory arthritis and symptoms ≤3 months' duration were tested. Patients were assigned to one of three outcome categories at 18-month follow-up (rheumatoid arthritis (RA), persistent non-RA arthritis and resolving arthritis).
    Results: Antibodies against citrullinated, carbamylated and acetylated vimentin peptides were detected in the sera of patients with early inflammatory arthritis. The proportion of patients seropositive for all antibody types was significantly higher in the RA group than in the other groups. Anti cyclic citrullinated peptide (CCP)-positive patients with RA had higher numbers of peptides recognised and higher levels of antibodies against those peptides, representing a distinct profile compared with the other groups.
    Conclusions: We show for the first time that antibodies against acetylated vimentin are present in the sera of patients with early RA and confirm and extend previous observations regarding anticitrullinated and anticarbamylated antibodies.
    MeSH term(s) Adult ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/immunology ; Autoantibodies/blood ; Autoantibodies/immunology ; Case-Control Studies ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Peptides, Cyclic/immunology ; Protein Processing, Post-Translational ; Vimentin/immunology
    Chemical Substances Autoantibodies ; Peptides, Cyclic ; Vimentin ; cyclic citrullinated peptide
    Language English
    Publishing date 2015-07-09
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2014-206785
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top